Motexafin gadolinium in the treatment of brain metastases

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 3, 2007, Pages 351-359

  Richards, Gregory M ^a   Mehta, Minesh P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Brain metastases; Brain radiation; Motexafin gadolinium; Radiosensitizer

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; DEXAMETHASONE; DOCETAXEL; EFAPROXIRAL; ERLOTINIB; GADOLINIUM TEXAPHYRIN; IBRITUMOMAB TIUXETAN; LAPATINIB; MISONIDAZOLE; MPC 6827; NSC 695238; PROCHLORPERAZINE; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADJUVANT THERAPY; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIARY TRACT TUMOR; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG UPTAKE; FECES; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTRON CAPTURE THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS TUMOR; PRURITUS; PSEUDOPORPHYRIA; QUALITY OF LIFE; RADIATION DOSE; RADIOSENSITIVITY; RADIOSURGERY; SCLERA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISCOLORATION; SKIN MANIFESTATION; SOLID TUMOR; SURVIVAL TIME; URINE; VESICULAR RASH;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CONTRAST MEDIA; GADOLINIUM; HUMANS; METALLOPORPHYRINS; PHOTOSENSITIZING AGENTS;

EID: 33847054651     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.3.351     Document Type: Article

References (55)

1. SAWAYA R: Intracranial metastases: current management strategies. (Ed.), Blackwell Futura, Malden, Mass, USA (2004) xiv: 497.
2. STEMMLER J, KAHLERT S, SIEKIERA W et al.: Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S).Abstr. 1568.
3. CAPPUZZO F, MAZZONI F, MAESTRI A et al.: Medical treatment of brain metastases from solid tumors. Forum (Genova) (2000) 10(2):137-148.
4. LOEFFLER JS, BARKER FG, CHAPMAN PH: Role of radiosurgery in the management of central nervous system metastases. Cancer Chemother. Pharmacol. (1999) 43 (Suppl.):S11-S14.
5. JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
6. LASSMAN AB, DEANGELIS LM: Brain metastases. Neurol. Clin. (2003) 21(1):1-23, vii.
7. LAGERWAARD FJ, LEVENDAG PC, NOWAK PJ et al.: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int. J. Radiat. Oncol. Biol. Phys. (1999) 43(4):795-803.
8. LANG EF, SLATER J: Metastatic Brain Tumors. Results of Surgical and Nonsurgical Treatment. Surg. Clin. North Am. (1964) 44:865-872.
9. RICHARDS P, MC KW: Intracranial metastases. Br. Med. J. (1963) 5322:15-18.
10. BORGELT B, GELBER R, KRAMER S et al.: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. (1980) 6(1):1-9.
11. BORGELT B, GELBER R, LARSON M et al.: Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. (1981) 7(12):1633-1638.
12. CHATANI M, MATAYOSHI Y, MASAKI N, INOUE T: Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther. Onkol. (1994) 170(3):155-161.
13. CHATANI M, TESHIMA T, HATA K, INOUE T: Prognostic factors in patients with brain metastases from lung carcinoma. Strahlenther. Onkol. (1986) 162(3):157-161.
14. HAIE-MEDER C, PELLAE-COSSET B, LAPLANCHE A et al.: Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother. Oncol. (1993) 26(2):111-116.
15. HARWOOD AR, SIMSON WJ: Radiation therapy of cerebral metastases: a randomized prospective clinical trial. Int. J. Radiat. Oncol. Biol. Phys. (1977) 2(11-12):1091-1094.
16. KURTZ JM, GELBER R, BRADY LW, CARELLA RJ, COOPER JS: The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. (1981) 7(7):891-895.
17. MURRAY KJ, SCOTT C, GREENBERG HM et al.: A randomized Phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int. J. Radiat. Oncol. Biol. Phys. (1997) 39(3):571-574.
18. PATCHELL RA, TIBBS PA, WALSH JW et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. (1990) 322(8):494-500.
19. ANDREWS DW, SCOTT CB, SPERDUTO PW et al.: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet (2004) 363(9422):1665-1672.
20. BHATNAGAR AK, FLICKINGER JC, KONDZIOLKA D, LUNSFORD LD: Stereotactic radiosurgery for four or more intracranial metastases. Int. J. Radiat. Oncol. Biol. Phys. (2006) 64(3):898-903.
21. VERGER E, GIL M, YAYA R et al.: Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a Phase II randomized trial. Int. J. Radiat. Oncol. Biol. Phys. (2005) 61(1):185-191.
22. ANTONADOU D, PARASKEVAIDIS M, SARRIS G et al.: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. (2002) 20(17):3644-3650.
23. HEDDE JP, KO Y, METZLER U et al.: A Phase I/II trial of topotecan and radiation therapy for CNS-metastases of patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22(Abstract 444):111.
24. JESSING K, MAUCK K, BRADFORD C et al.: MPC-6827, a small molecule inhibitor of microtubule formation with high brain penetration: absorption, distribution, metabolism, excretion, and clinical considerations. AACR Meeting Abstracts (2005) 2005(1):804.
25. PAUL MJ, SUMMERS Y, CALVERT AH et al.: Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. (2002) 12(2):175-178.
26. LIN NU, CAREY LA, LIU MC et al.: Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):3S.
27. PHILLIPS TL, SCOTT CB, LEIBEL SA, ROTMAN M, WEIGENSBERG IJ: Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int. J. Radiat. Oncol. Biol. Phys. (1995) 33(2):339-348.
28. KOMARNICKY LT, PHILLIPS TL, MARTZ K et al.: A randomized Phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat. Oncol. Biol. Phys. (1991) 20(1):53-58.
29. SHAW E, SCOTT C, SUH J et al.: RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain metastases Database. J. Clin. Oncol. (2003) 21(12):2364-2371.
30. SUH J, STEA B, NABID A et al.: Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral)in patients with brain metastases: Results of the randomized REACH (RT-009) study. Proc. Am. Soc. Clin. Oncol. (2004) 22(14S):115S.
31. SUH JH, STEA B, NABID A et al.: Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol. (2006) 24(1):106-114.
32. KHUNTIA D, MEHTA M: Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev. Anticancer Ther. (2004) 4(6):981-989.
33. HASHEMY SI, UNGERSTEDT JS, ZAHEDI AVVAL F, HOLMGREN A: Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem. (2006) 281(16):10691-10697.
34. MAGDA D, LEPP C, GERASIMCHUK N et al.: Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51(4):1025-1036.
35. YOUNG SW, QING F, HARRIMAN A et al.: Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA (1996) 93(13):6610-6615.
36. MODY TD, FU L, SESSLER JL: Texaphyrins: Synthesis and Development of a Novel Class of Therapeutic Agents. In: Progress in Inorganic Chemistry. Karlin KD (Ed.) Wiley, New York (2001):551-598.
37. MAGDA D, LECANE P, MILLER RA et al.: Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res. (2005) 65(9):3837-3845.
38. LECANE PS, KARAMAN MW, SIRISAWAD M et al.: Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. (2005) 65(24):11676-11688.
39. MILLER RA, WOODBURN K, FAN Q et al.: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int. J. Radiat. Oncol. Biol. Phys. (1999) 45(4):981-989.
40. WOODBURN KW: Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J. Pharmacol. Exp. Ther. (2001) 297(3):888-894.
41. BERNHARD EJ, MITCHELL JB, DEEN D et al.: Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Res. (2000) 600):86-91.
42. ROSENTHAL DI, NURENBERG P, BECERRA CR et al.: A Phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin. Cancer Res. (1999) 5(4):739-745.
43. ROSENTHAL DI, BECERRA CR, TOTO RD, CARBONE DP, FRENKEL EP: Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin. Am. J. Clin. Oncol. (2000) 23(6):593-598.
44. VIALA J, VANEL D, MEINGAN P et al.: Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology (1999) 212(3):755-759.
45. CARDE P, TIMMERMAN R, MEHTA MP et al.: Multicenter Phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J. Clin. Oncol. (2001) 19(7):2074-2083.
46. RAMANATHAN RK, FAKIH M, MANI S et al.: Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother. Pharmacol. (2006) 57(4):465-474.
47. MEHTA MP, SHAPIRO WR, GLANTZ MJ et al.: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J. Clin. Oncol. (2002) 20(16):3445-3453.
48. MEHTA MP, RODRIGUS P, TERHAARD CH et al.: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. (2003) 21(13):2529-2536.
49. MEYERS CA, SMITH JA, BEZJAK A et al.: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized Phase III trial. J. Clin. Oncol. (2004) 22(1):157-165.
50. MEHTA MP, GERVAIS R, CHABOT P et al.: Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a Phase III trial. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):Abstract 7014.
51. FORD JM, ENDICOTT T, ALGER JR et al.: A Phase I dose escalation trial of motexafin gadolinium as a radiation sensitizer in patients with newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51(3S1):205.
52. FORD JM, SEIFERHELD W, MEHTA M, PHAN S, CURRAN W: Comparison of survival of patients in the Phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database. Proc. Am. Soc. Clin. Oncol. (2003) 22(Abstr. 425):106.
53. SUH J, MEHTA MP, CHANG E et al.: Phase II trial of motexafin gadolinium and cranial radiation in newly diagnosed glioblastoma multiforme (GBM). Int. J. Radiat. Oncol. Biol. Phys. (2002) 54(2S):246.
54. MEHTA M, FORD JM, SUH J, PHAN S: Cumulative dose of motexafin gadolinium (MGD) and survival in newly diagnosed glioblastoma multiforme (GBM). Neuro-Oncology (2004) 6(4):378.
55. DE STASIO G, RAJESH D, FORD JM et al.: Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei. Clin. Cancer Res. (2006) 12(1):206-213.